Cary Street Partners Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$546K Buy
18,865
+1,238
+7% +$36.1K 0.07% 145
2024
Q2
$493K Buy
17,627
+286
+2% +$7.87K 0.07% 149
2024
Q1
$481K Buy
17,341
+973
+6% +$27K 0.07% 148
2023
Q4
$471K Buy
16,368
+27
+0.2% +$816 0.08% 144
2023
Q3
$542K Sell
16,341
-3,925
-19% -$139K 0.1% 137
2023
Q2
$743K Buy
20,266
+16
+0.1% +$623 0.14% 119
2023
Q1
$826K Sell
20,250
-1
-0% -$43 0.16% 105
2022
Q4
$1.04M Buy
20,251
+2,001
+11% +$95.9K 0.21% 97
2022
Q3
$799K Sell
18,250
-4,816
-21% -$234K 0.19% 98
2022
Q2
$1.21M Buy
23,066
+100
+0.4% +$5.1K 0.28% 85
2022
Q1
$1.19M Buy
22,966
+4,441
+24% +$230K 0.24% 93
2021
Q4
$1.09M Hold
18,525
0.23% 101
2021
Q3
$797K Sell
18,525
-1,000
-5% -$44.3K 0.28% 92
2021
Q2
$765K Hold
19,525
0.18% 107
2021
Q1
$707K Buy
+19,525
New +$693K 0.17% 111

Other funds holding PFE

Cary Street Partners Asset Management's PFE Position: Q3 2024 in Review

Cary Street Partners Asset Management increased its Pfizer (PFE) stake by 7% in Q3 2024, buying an estimated $36.1K and bringing the position to 18,865 shares worth $546K. The position accounts for 0.07% of the portfolio, ranked #145.

Cary Street Partners Asset Management first reported a position in PFE in Q1 2021 and has held it in 15 quarters since. The position peaked at $1.21M in Q2 2022. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.

  • Cary Street Partners Asset Management held 18,865 shares of Pfizer worth $546K as of Q3 2024.
  • Cary Street Partners Asset Management bought 1,238 Pfizer shares in Q3 2024, an estimated $36.1K.
  • Pfizer made up 0.07% of Cary Street Partners Asset Management's portfolio in Q3 2024, its #145 holding.
  • Cary Street Partners Asset Management first reported a position in Pfizer in Q1 2021 and has held it in 15 quarters since.
  • Cary Street Partners Asset Management's Pfizer position peaked at $1.21M in Q2 2022.
  • 2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.

Based on Cary Street Partners Asset Management's 13F filing for Q3 2024, filed 30 Oct 2024.